Routine sequencing of BRAF exon 15 improves therapeutic stratification for metastatic melanoma
- 22 November 2025
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (6) , 841-844
Abstract
Objective: BRAF V600E/K mutations are significant drivers of metastatic melanoma, and therapies that selectively target these mutations have significantly improved patient long-term survival. Emerging evidence suggests that tumors harboring BRAF non-V600E/K mutations are susceptible to MEK-targeting therapies, but these mutations are not always assessed in clinical workup. To assess whether patient stratification for targeted therapy can be improved, we characterized the prevalence and nature of BRAF non-V600E/K mutations in a cohort of patients diagnosed with metastatic melanoma. Methods: We extracted DNA from 99 specimens collected between June 2019 and September 2021. The samples were analyzed using next-generation sequencing to identify mutations in BRAF exon 15 and to assess their susceptibility to targeted therapies. Results: Eleven percent of patient specimens contained BRAF non-V600E/K mutations in exon 15. Of the mutations identified, all have prior evidence of susceptibility to targeted MEK therapies. Among those patients, less than half received targeted MEK therapies. Conclusions: Next-generation sequencing is a sensitive platform for profiling BRAF exon 15 mutations that cannot be detected by other techniques. Our results support the routine sequencing of BRAF exon 15 to improve patient stratification for therapy.Keywords
This publication has 24 references indexed in Scilit:
- Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019JAMA Network Open, 2022
- Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II StudyThe Oncologist, 2021
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaNature Medicine, 2019
- Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanomaVirchows Archiv, 2018
- Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutationsOncogene, 2018
- Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicineLaboratory Investigation, 2018
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASNature, 2017
- Whole-genome landscapes of major melanoma subtypesNature, 2017
- BRAF inhibitor activity in V600R metastatic melanomaEuropean Journal of Cancer, 2013
- Detection of BRAF p.V600E Mutations in MelanomasThe Journal of Molecular Diagnostics, 2013